NCT02578797View on ClinicalTrials.gov

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

September 20, 2016

Study Completion Date

October 13, 2022

Conditions
Castration-Resistant Prostate Cancer
Interventions
DRUG

Apalutamide

Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.

Trial Locations (5)

Unknown

Greenville

Montreal

Chisinau

Rotterdam

Sutton

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY